Publications
880
Citations
32,205
Est. group size
~36
Recurring co-author estimate
Active years
48
Publishing since 1979
David M. O'Malley is a physician-researcher focused on gynecologic cancers, particularly ovarian, endometrial, and cervical cancer. His work centers on testing new drugs and drug combinations in clinical trials, including targeted therapies, immunotherapies, and antibody-drug conjugates, aiming to improve treatment options for patients with these cancers. Much of the research involves large multi-site clinical trials evaluating safety, effectiveness, and biological markers that predict treatment response.
Publication output grew substantially from the late 2010s through 2023, peaking at 135 papers that year, before declining somewhat in 2024-2025, though output remains well above earlier-decade levels.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
Journal for ImmunoTherapy of Cancer · 2026
- HO-3867 reprograms the tumor microenvironment through extracellular vesicle regulation in ovarian cancer
Academia oncology. · 2026
- Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma
The Medicine Forum · 2026
- Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian Carcinoma
Cells · 2026
- Abstract CT306: Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors: Part 1 dose-escalation results
Cancer Research · 2026
- Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer
Cancer Research · 2026
- Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
The Lancet · 2025
- Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Journal of Clinical Oncology · 2025
- Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial
Nature Cancer · 2025
- Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
The Lancet Oncology · 2025
- Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
Gynecologic Oncology · 2025
- Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial
Nature Communications · 2025
- Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Nature Medicine · 2025
- Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study
European Journal of Cancer · 2025
- Uterine leiomyosarcoma
International Journal of Gynecological Cancer · 2025
- Gynecologic Oncology×179
- Journal of Clinical Oncology×85
- International Journal of Gynecological Cancer×67
- Annals of Oncology×49
- Clinical Cancer Research×16
- Larry J. Copeland
Medicine · The Ohio State University
- Monica Levine
Medicine · The Ohio State University
- Laura Chambers
Medicine · The Ohio State University
- Stephanie V. Blank
Medicine · The Ohio State University
- John L. Hays
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile